SCIENCE@home

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a

E. T. Lim,A. Petzold,S. Leary,D. Altmann,G. Keir,E. Thompson,David H. Miller,A. Thompson,G. Giovannoni

Published 2001 in Journal of Negative Results in Biomedicine

ABSTRACT

S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled trial of Interferon β-1a in subjects with PPMS. The key questions were whether S100B levels were associated with either disability or MRI findings in primary progressive MS and whether Interferon β-1a has an effect on their S100B levels. Serial serum S100B levels were measured using an ELISA method. The results demonstrated that serum S100B is not related to either disease progression or MRI findings in subjects with primary progressive MS given Interferon β-1a. Furthermore there is no correlation between S100B levels and the primary and secondary outcome measures.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-27 of 27 references · Page 1 of 1

CITED BY

Showing 1-12 of 12 citing papers · Page 1 of 1